Nexlizet - (180 mg/10 mg ; Tablet)

Generic Name	Bempedoic Acid and Ezetimibe	Innovator	Esperion Theraps INC
Dosage	180 mg/10 mg ; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	NEXLIZET, which contains an adenosine triphosphate-citrate lyase (ACL) inhibitor and a cholesterol absorption inhibitor, is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
** *****'*	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events